CORE--VIROLOGY CORE LABORATORY

核心病毒学实验室将负责执行方案 强制进行病毒学检测 这将有助于ACTU在这个机构， 以及其他没有病毒学核心实验室的ACTG单位。 艾滋病毒，巨细胞病毒， 将在基线时进行EBV、VZV和HSV血清学研究， 此后，根据临床方案的要求。 Priestion，initial 基线病毒学测定将在开始 治疗，并在此后的频繁间隔，这些将包括病毒 分离和HIV血清P-24 Ag测定。 艾滋病毒隔离将是 外周血，除非方案另有规定。 HIV血浆 当有指征时，病毒血症可被确定为 抗逆转录病毒治疗效果。 病毒学核心也会分离出 并量化其他通常感染HIV患者的机会性病毒， 特别是巨细胞病毒（CMV）、单纯疱疹病毒（HSV），和 腺病毒。 定量CMV尿培养可用作 抗巨细胞病毒治疗效果的标志物。 回收的所有分离株 将储存接受特定抗病毒治疗的患者的样本以供使用， 需要进行抗病毒药物耐药性测试。 快速CMV培养物回收可 使用壳瓶离心法进行。 灵敏度 测试患者来源的病毒分离物对抗病毒化合物（例如， 更昔洛韦耐药CMV和阿昔洛韦耐药HSV）将按照 needed. 测量HIV标志物的其他替代标志物，如gp 120， nef蛋白、新喋呤、B2微球蛋白和C1 q以及其他标记物， 研究方案所示。 此外，实验室将继续 参与开发和评估新型病毒学诊断 工具，因为他们成为可用的，并在现有的修改 提高其敏感性和具体性的方法。 的 实验室也将参与质量保证计划 由ACTG建立，以标准化获得的结果。

The core virology laboratory will be responsible for performing protocol mandated virology testing. This will serve the ACTU in this institution as well as other ACTG units without virology core laboratories. HIV, CMV, EBV, VZV, and HSV serologic studies will be performed at baseline and thereafter as mandated by the clinical protocol. Primarily, initial baseline virology determinations will be done before the initiation of therapy, and at frequent intervals thereafter, these will include virus isolations and HIV serum P-24 Ag determinations. HIV isolations will be from peripheral blood, unless protocol mandates otherwise. HIV plasma viremia may be determined, when indicated, as a potential marker of antiretroviral therapeutic efficacy. The virology core will also isolate and quantify other opportunistic viruses that commonly infect HIV patients, particularly cytomegalovirus (CMV), herpes simplex virus (HSV), and adenovirus. Quantitative CMV urine cultures are available for use as a marker of anticytomegaloviral therapeutic efficacy. All isolates recovered from patients on specific antiviral therapy will be stored for use, as needed, for antiviral resistance testing. Rapid CMV culture recovery may be facilitated using the shell vial centrifugation method. Sensitivity testing of patient derived viral isolates to antiviral compounds (e.g. ganciclovir-resistant CMV and acyclovir-resistant HSV) will be done as needed. Measurement of other surrogate markers of HIV markers as gp120, nef protein, neopterin, B2 microglobulin, and C1q and other markers as indicated by study protocols. Moreover, the laboratory will continue to be involved in the development and evaluation of novel virology diagnostic tools as they become available and in the modification of existent methodologies to increase their sensitivities and specificities. The laboratory will also participate in the quality assurance program established by the ACTG in order to standardize the results obtained.